Product Description: Ro 25-6981 Maleate is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 Maleat shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 Maleate has the potential for the research of parkinson's disease (PD)[1][2][3].
Applications: Neuroscience-Neurodegeneration
Formula: C26H33NO6
Citations: Neurochem Int. 2020 Dec 16;104942./Sci Rep. 2022 Oct 12;12(1):17114./Cell Death Differ. 2023 May 4./CNS Neurosci Ther. 2023 Jan 24./Exp Brain Res. 2023 Oct 16./Neuropharmacology. 2022 Jan 10;108947.
References: [1]Löschmann PA, et al. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp Neurol. 2004 May;187(1):86-93./[2]Szczurowska E,et al. Different action of a specific NR2B/NMDA antagonist Ro 25-6981 on cortical evoked potentials and epileptic afterdischarges in immature rats. Brain Res Bull. 2015 Feb;111:1-8./[3]Jiang M, et al. Antinociception and prevention of hyperalgesia by intrathecal administration of Ro 25-6981, a highly selective antagonist of the 2B subunit of N-methyl-D-aspartate receptor. Pharmacol Biochem Behav. 2013 Nov;112:56-63.
CAS Number: 1312991-76-6
Molecular Weight: 455.54
Compound Purity: 99.25
Research Area: Neurological Disease
Solubility: DMSO : 100 mg/mL (ultrasonic)/H2O : 8.33 mg/mL (ultrasonic;warming;heat to 45°C)
Target: iGluR
English
Deutsch
